The genetics of cardiovascular disease: From genotype to phenotype

Dialogues in Cardiovascular Medicine

Volumn 9, Issue 1, 2004, Pages 3-19

  Sanders Williams, R ^a   Goldschmidt Clermont, Pascal J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cardiomyopathy; Genome; Genotype; Hypertension; Phenotype

Indexed keywords

ACTIN; ADENYLATE KINASE; ALDOSTERONE SYNTHASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CONNECTIN; DESMIN; DYSTROBREVIN; DYSTROPHIN; GLUCOCORTICOID; GLUCOKINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIN A; LAMIN C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MINERALOCORTICOID RECEPTOR; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; SARCOGLYCAN; SODIUM; STEROID 11BETA MONOOXYGENASE; TRANSCRIPTION FACTOR; TROPOMYOSIN; TROPONIN T;

ALKALOSIS; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT INHERITANCE; CARDIOLOGY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONGENITAL HEART MALFORMATION; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; FAMILIAL DISEASE; GENE TECHNOLOGY; GENETIC DISORDER; GENETIC EPIDEMIOLOGY; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GREAT BLOOD VESSEL; HEALTH CARE FACILITY; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HERITABILITY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MEDICAL GENETICS; MEDICAL LITERATURE; MEDICAL SPECIALIST; MOLECULAR GENETICS; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PHENOTYPE; PHYSICIAN; REVIEW; STROKE; SUDDEN DEATH; VALVULAR HEART DISEASE; WOLFF PARKINSON WHITE SYNDROME; X CHROMOSOME LINKAGE;

EID: 2342426801     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Breslow JL. Genetic markers for coronary heart disease. Clin Cardiol. 2001;24(7 suppl):II14-II17.
2. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39:27-38.
3. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA. 1989;86:587-591.
4. Hu FL, Gu Z, Kozich V, Kraus JP, Ramesh V, Shih VE. Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. Hum Mol Genet. 1993;2:1857-1860.
5. Scott HS, Litjens T, Hopwood JJ, Morris CP. A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype. Hum Mutat. 1992;1:103-108.
6. Goldfischer S, Coltoff-Schiller B, Biempica L, Wolinsky H. Lysosomes and the sclerotic arterial lesion in Hurler's disease. Hum Pathol. 1975;6:633-637.
7. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556.
8. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12:24-30.
9. + channel. Cell. 1995;83:969-978.
10. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119-123.
11. Towbin JA, Bowles NE. The failing heart. Nature. 2002;415:227-233.
12. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104:557-567.
13. Schonberger J, Seidman CE. Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. Am J Hum Genet. 2001;69:249-260.
14. Emery AE. The muscular dystrophies. Lancet. 2002;359:687-695.
15. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
16. Priori SG. Long QT and Brugada syndromes: from genetics to clinical management. J Cardiovasc Electrophysiol. 2000;11:1174-1178.
17. Gollob MH, Seger JJ, Gollob TN, et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation. 2001;104:3030-3033.
18. Wang O, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.
19. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-339.
20. Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT. The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell. 1993;73:159-168.
21. Basson CT, Bachinsky DR, Lin RC, et al. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet. 1997;15:30-35.
22. Benson DW, Silberbach GM, Kavanaugh-McHugh A, et al. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest. 1999;104:1567-1573.
23. Wallace DC. Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am Heart J. 2000;139(2, pt 3):S70-S85.
24. Coral-Vazquez R, Cohn RD, Moore SA, et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 1999;98:465-474.
25. Bodmer R. The gene tinman is required for specification of the heart and visceral muscles in Drosophila. Development. 1993;118:719-729.
26. Davies K. Cracking the Genome. New York, NY: The Free Press; 2001.
27. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
28. Williams RS. Calcium-dependent gene regulation in myocyte hypertrophy and remodeling. In: Cold Spring Harbor Symposia on Quatitative Biology - The Cardiovascular System. Cold Spring Harbor, NY; 2002. In press.
29. Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem. 2000;275:8719-8725.
30. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98:3328-3333.
31. Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem. 2002;277:10251-10255.
32. Arber S, Hunter JJ, Ross J Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997;88:393-403.
33. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99:313-322.
34. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA. 1998;95:7000-7005.
35. Suzuki M, Carlson KM, Marchuk DA, Rockman HA. Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation. 2002;105:1824-1829.
36. Steinmetz LM, Sinha H, Richards DR, et al. Dissecting the architecture of a quantitative trait locus in yeast. Nature. 2002;416:326-330.
37. Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell. 2002;108:145-152.
38. Kruglyak L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet. 1999;22:139-144.
39. Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature. 2001;411:199-204.
40. Ponder BA. Cancer genetics. Nature. 2001;411:336-341.
41. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041-1046.
42. Goldschmidt-Clermont PJ, Cooke GE, Eaton GM, Binkley PF. PlA2, a variant of GPIIIa implicated in coronary thromboembolic complications. J Am Coll Cardiol. 2000;36:90-93.
43. Mikkelsson J, Perola M, Kauppila LI, et al. The GPIIIa Pl(A) polymorphism in the progression of abdominal aortic atherosclerosis. Arteriosclerosis. 1999;147:55-60.
44. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 1997;349:385-388.
45. Goldschmidt-Clermont P, Roos C, Cooke GE. Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. J Thromb Thrombolysis. 2000;8:89-103.
46. Kandzari DE, Goldschmidt-Clermont PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. J Am Coll Cardiol. 2001;38:1028-1032.
47. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol. 2000;86:1000-1005, A8.
48. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999;19:1142-1147.
49. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet. 1998;351:1253.
50. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192.